ifosfamide has been researched along with Leukemia L 1210 in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The series of 9 compounds, including 3 racemates and 6 enantiomers of bromine-substituted analogues of ifosfamide (bromo-, chlorobromo- and dibromofosfamides) have been evaluated for antitumor activity against L1210 leukemia, Lewis lung carcinoma and B16 melanoma in mice." | 3.68 | Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds. ( Glazman-Kuśnierczyk, H; Matuszyk, J; Radzikowski, C, 1992) |
| "Dose-effect relations have been evaluated by the treatment of cell cultures (9L glioma cells of rat as monolayers and tumor spheroids, L 1210 cells of mice) with activated isophosphamide, adriamycin, epirubicin and 6 MeV electrons." | 3.68 | Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 2: Dose-effect relationships and 31P NMR spectroscopy of L 1210 cells (monolayers) and 9L glioma cells (monolayers and tumor spheroids) treated with activated is ( Ulmer, W, 1991) |
| "The biologic activity in terms of survival of normal hematopoietic stem, osteosarcoma, and L1210 leukemia cells was determined for the following compounds:cyclophosphamide, its derivatives isophosphamide and trophosphamide, its possible metabolites nor-nitrogen mustard, hydroxylamine mustard, 4-ketocyclophosphamide, and and acrolein, and two substitutes for its primary active metabolite 4-hydroxycyclosphamide anhydro-dimer (4-hydroxy-CP-anhydro-dimer) and 4-hydroperoxycyclophosphamide (4-hydroperoxy-CP)." | 3.65 | Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271). ( Lelieveld, P; van Putten, LM, 1976) |
| " The combination treatments with 6-thioguanine and each of six agents, especially with ACNU, showed a distinct therapeutic effect against the early L-1210 leukemia at dosage levels not producing any significant antitumor activity with each agent alone (ip-ip)." | 1.26 | Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210. ( Fujimoto, S; Horikoshi, N; Hoshino, A; Inagaki, J, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (59.09) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takamizawa, A | 3 |
| Matsumoto, S | 2 |
| Iwata, T | 3 |
| Makino, I | 2 |
| Yamaguchi, K | 2 |
| Uchida, N | 1 |
| Kasai, H | 1 |
| Shiratori, O | 2 |
| Takase, S | 1 |
| Misiura, K | 4 |
| Kinas, RW | 3 |
| Stec, WJ | 2 |
| Kusnierczyk, H | 5 |
| Radzikowski, C | 4 |
| Sonoda, A | 1 |
| Ludeman, SM | 1 |
| Boyd, VL | 1 |
| Regan, JB | 1 |
| Gallo, KA | 1 |
| Zon, G | 1 |
| Ishii, K | 1 |
| Goldin, A | 1 |
| Phelan, ET | 1 |
| Vietti, TJ | 1 |
| Valeriote, FA | 1 |
| Coulter, D | 1 |
| Kutscher, B | 1 |
| Niemeyer, U | 1 |
| Engel, J | 1 |
| Kleemann, A | 1 |
| Hilgard, P | 1 |
| Pohl, J | 1 |
| Scheffler, G | 1 |
| Struck, RF | 2 |
| Schmid, SM | 1 |
| Waud, WR | 1 |
| Kardacka, K | 1 |
| Carter, SK | 1 |
| Slavik, M | 1 |
| Fujimoto, S | 1 |
| Inagaki, J | 1 |
| Horikoshi, N | 1 |
| Hoshino, A | 1 |
| Hohorst, HJ | 1 |
| Peter, G | 1 |
| Lelieveld, P | 1 |
| van Putten, LM | 1 |
| Harada, M | 1 |
| Glazman-Kuśnierczyk, H | 1 |
| Matuszyk, J | 2 |
| Ulmer, W | 2 |
| Berenbaum, MC | 1 |
| Skórski, T | 1 |
| Kawalec, M | 1 |
| Hoser, G | 1 |
2 reviews available for ifosfamide and Leukemia L 1210
| Article | Year |
|---|---|
Ifosfamide in experimental tumor systems.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Ifosfamide; Lethal Dose | 1982 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Ant | 1976 |
20 other studies available for ifosfamide and Leukemia L 1210
| Article | Year |
|---|---|
Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
Topics: Alkylating Agents; Animals; Cell Survival; Cyclophosphamide; Ifosfamide; In Vitro Techniques; Leukem | 1978 |
Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Female; Ifosfamide; Indicators and Reagents; Leuke | 1988 |
Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of "phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.
Topics: Animals; Antineoplastic Agents; Cyanides; Cyclophosphamide; Half-Life; Hydrogen-Ion Concentration; K | 1986 |
Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
Topics: Animals; Antineoplastic Agents, Alkylating; Hydroxylation; Ifosfamide; Isotope Labeling; Kinetics; L | 2002 |
Comparison of cytotoxic action of iphosphamide and cyclophosphamide.
Topics: Animals; Cell Line; Cell Survival; Colony-Forming Units Assay; Cyclophosphamide; Dose-Response Relat | 1981 |
Synthesis and antitumor activity of two ifosfamide analogs with a five-membered ring.
Topics: Animals; Antineoplastic Agents; Ifosfamide; Lethal Dose 50; Leukemia L1210; Magnetic Resonance Spect | 1995 |
Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Screening Assays, Antitumor; Humans; Ifosfami | 1994 |
(S)-(-)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Availability; Carcinoma, Lewis Lung; Chromato | 2001 |
Synthesis, in vitro metabolic studies, and antitumour activity of methyl analogues of ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Ifosfamide; Leukemia L1210; Mice; Structure-Activity Rel | 2001 |
Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Female | 1977 |
Synthesis, stereochemistry and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and related compounds.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Ifosfamide; Leukemia L1210; Mice; Molecular Confor | 1977 |
Synthesis of 4-hydroperoxy derivatives of ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Cyclophosphamide; Drug Evaluation, Pr | 1976 |
Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Topics: Acrolein; Animals; Antineoplastic Agents; Biotransformation; Cells, Cultured; Cyclophosphamide; Dose | 1976 |
Stereochemistry, metabolism, and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and its stereoisomer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cells, Cultured; Chemical Phenomena; Chemi | 1976 |
Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds.
Topics: Animals; Bromine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ifosfamide; Le | 1992 |
Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 1: In vitro investigations on the kinetics of activated isophosphamide metabolites and the determination of selective properties of DNA-interstrand and DNA-prote
Topics: Alkylation; Animals; Antineoplastic Agents; Biophysical Phenomena; Biophysics; Combined Modality The | 1991 |
Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 2: Dose-effect relationships and 31P NMR spectroscopy of L 1210 cells (monolayers) and 9L glioma cells (monolayers and tumor spheroids) treated with activated is
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biophysical Phenomena; Biophysics; Cell Lin | 1991 |
Direct search methods in the optimisation of cancer chemotherapy regimens.
Topics: Acetylcysteine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1990 |
Comparative evaluation of acute toxicity and antitumor activity of IF-XXV preparation and holoxan.
Topics: Animals; Female; Ifosfamide; Lethal Dose 50; Leukemia L1210; Lung Neoplasms; Male; Mice; Mice, Inbre | 1989 |
Cyclophosphamide- or ifosfamide-treated L 1210 leukaemia cells: immunogenicity, viability and metabolism.
Topics: Animals; Antigens, Neoplasm; Cell Division; Cyclophosphamide; DNA, Neoplasm; Histocompatibility Anti | 1986 |